All In Biotech

Drug Trial Radar · NCT07074327

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Phase 1, Open-label Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

74

Actual

Start

Jul 11, 2025

Primary completion

Feb 20, 2026

Study completion Feb 27, 2026

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Jul 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.

Conditions

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

  • VX-407Drug

    Suspension for oral administration.

  • LNG/EEDrug

    Combination Tablets for Oral Administration.

  • NGM/EEDrug

    Combination Tablets for Oral Administration.

  • NET/EEDrug

    Combination Tablets for Oral Administration.

  • DRSP/EEDrug

    Combination Tablets for Oral Administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of LNG and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
  2. Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
  3. Part B (Optional): Cmax of Norelgestromin (NGMN) and Norgestrel (NG) (Active Metabolites of NGM) and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31
  4. Part B (Optional): AUC0-inf of NGMN and NG (Active Metabolites of NGM) and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31
  5. Part C (Optional): Cmax of NET and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23
  6. Part C (Optional): AUC0-inf of NET and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23
  7. Part D (Optional): Cmax of DRSP and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
  8. Part D (Optional): AUC0-inf of DRSP and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences - Kansas City

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.